Copper Balance in Healthy Participants Administered ALXN1840
Status:
Completed
Trial end date:
2020-11-17
Target enrollment:
Participant gender:
Summary
The study will assess the change from baseline in mean daily copper balance in healthy
participants with repeat-dose administrations of ALXN1840 over 2 weeks.